Moderna
FDA Approves Moderna’s RSV Vaccine, Marking Its Second Commercial Product
Moderna, RSV Vaccine, FDA Approval, mRNA Technology, Respiratory Syncytial Virus, COVID-19, Spikevax, mRESVIA
Moderna Secures Victory in EU Patent Dispute with Pfizer-BioNTech over COVID-19 Vaccine
Moderna, Pfizer, BioNTech, EU, patent dispute, COVID-19 vaccine, mRNA technology, European Patent Office (EPO), intellectual property rights, pharmaceutical industry.
Moderna’s Diversification Strategy Hindered by FDA Delay in RSV Vaccine Review
Moderna, FDA, RSV vaccine, diversification strategy, vaccine review, delay
Moderna’s RSV Vaccine Decision Postponed by FDA to Late May
FDA, Moderna, RSV vaccine, decision, delay, May
Moderna Terminates Gene Editing Partnership, Shifts Focus to mRNA Technology
Moderna, Metagenomi, gene editing, partnership, mRNA technology, biotechnology, biobucks, deal termination
Moderna Maintains Long-Term Vision, Terminates Collaboration with Metagenomi
Moderna, first-quarter update, long-term strategy, Metagenomi, collaboration termination
Moderna Collaborates with OpenAI for Seamless Integration of GenAI in Operations
Moderna, OpenAI, GenAI, seamless integration, operations, biotechnology, artificial intelligence, partnership
Delaware Judge Rules in Favor of Roivant Subsidiary Arbutus in COVID-19 Vaccine Patent Dispute with Moderna
Moderna, Arbutus Biopharma, Roivant Sciences, COVID-19 vaccine, Patent infringement, Judge Mitchell Goldberg, Lipid nanoparticles (LNP), Claim construction order